BALDO LANCE
Known title: Chief Medical OfficerCIK: 0001780773
Associated companies
Transaction History
| ADPT | ▼ Sell | Open Market | 3,350 | $38K | 3/8/2022 | View on chart |
| ADPT | ▼ Sell | Open Market | 2,373 | $28K | 3/7/2022 | View on chart |
| ADPT | ▼ Sell | Open Market | 3,350 | $38K | 3/8/2022 | View on chart |
| ADPT | ▼ Sell | Open Market | 2,373 | $28K | 3/7/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism
Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism. Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.